AssetMark Inc
HZNP

AssetMark Inc’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

AssetMark Inc’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-512
Closed -$52.7K – 1830
2023
Q2 		$52.7K Buy
512
+126
+33% +$13.3K ﹤0.01% 1062
2023
Q1 		$42.1K Sell
386
-702
-65% -$77.6K ﹤0.01% 1072
2022
Q4 		$124K Buy
1,088
+55
+5% +$4.57K ﹤0.01% 883
2022
Q3 		$64K Buy
1,033
+131
+15% +$9.15K ﹤0.01% 903
2022
Q2 		$72K Buy
902
+565
+168% +$53.5K ﹤0.01% 864
2022
Q1 		$35K Buy
+337
New +$32.8K ﹤0.01% 986
2021
Q2 		– Sell
-2
Closed – – 1612
2021
Q1 		$0 Hold
2
– – ﹤0.01% 1590
2020
Q4 		$0 Sell
2
-11
-85% -$818 ﹤0.01% 1528
2020
Q3 		$1K Sell
13
-8,482
-100% -$584K ﹤0.01% 1303
2020
Q2 		$472K Sell
8,495
-141,319
-94% -$6.05M ﹤0.01% 393
2020
Q1 		$4.44M Buy
149,814
+60,625
+68% +$2.05M 0.04% 227
2019
Q4 		$3.23M Buy
89,189
+89,072
+76,130% +$2.73M 0.02% 284
2019
Q3 		$3K Buy
117
+26
+29% +$672 ﹤0.01% 1137
2019
Q2 		$2K Buy
91
+29
+47% +$736 ﹤0.01% 1205
2019
Q1 		$2K Buy
62
+18
+41% +$427 ﹤0.01% 1208
2018
Q4 		$1K Hold
44
– – ﹤0.01% 1403
2018
Q3 		$1K Sell
44
-11
-20% -$209 ﹤0.01% 1390
2018
Q2 		$1K Hold
55
– – ﹤0.01% 1387
2018
Q1 		$1K Buy
55
+13
+31% +$192 ﹤0.01% 1385
2017
Q4 		$1K Buy
+42
New +$590 ﹤0.01% 1812
2016
Q1 		– Sell
-47
Closed -$1K – 1502
2015
Q4 		$1K Buy
47
+34
+262% +$662 ﹤0.01% 1325
2015
Q3 		$0 Buy
+13
New +$411 ﹤0.01% 896

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AssetMark Inc's HZNP Position: Q3 2023 in Review

AssetMark Inc sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 512 shares — an estimated $52.7K sold.

AssetMark Inc first reported a position in HZNP in Q3 2015 and held it in 22 quarters. The position peaked at $4.44M in Q1 2020. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • AssetMark Inc reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • AssetMark Inc sold 512 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $52.7K.
  • AssetMark Inc first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 22 quarters.
  • AssetMark Inc's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.44M in Q1 2020.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on AssetMark Inc's 13F filing for Q3 2023, filed 27 Oct 2023.